Relationship between pan-immune inflammation value and clinicopathological features of non-small cell lung cancer and predictive analysis for bone metastasis

doi:10.3760/cma.j.cn371439-20250919-00034

Abstract

Abstract:

Objective To investigate the relationship between pan-immune inflammation value （PIV） and clinicopathological features of non-small cell lung cancer （NSCLC）， and its predictive effect on bone metastasis. Methods A retrospective analysis was conducted on the clinical data of 157 NSCLC patients admitted to the 909th Hospital （Dongnan Hospital of Xiamen University） from January 2020 to December 2022. According to the occurrence of bone metastasis， the patients were divided into bone metastasis group （n=57） and non-metastasis group （n=100）. The differences of PIV among NSCLC patients with different clinicopathological features were compared. The receiver operator characteristic （ROC） curve was used to analyze the predictive value of PIV for bone metastasis in NSCLC patients， and the differences of clinicopathological features between the two groups were compared. Multivariate logistic regression analysis was used to identify the influencing factors for bone metastasis in NSCLC patients. Results The PIVs of patients with tumor longest diameter ≥3 cm （t=-3.09， P=0.002）， lymph node metastasis （t=2.80， P=0.006）， TNM stage Ⅲ （t=-3.56， P=0.001）， and bone metastasis （t=13.39， P<0.001） were all higher than those of patients with tumor longest diameter <3 cm， without lymph node metastasis， TNM stage Ⅰ-Ⅱ， and without bone metastasis. ROC curve analysis showed that the area under the curve of PIV for predicting bone metastasis in NSCLC patients was 0.946 （95%CI： 0.912-0.979）， with the optimal cut-off value of 424.5， sensitivity of 0.732 and specificity of 0.990. The proportions of patients with tumor longest diameter ≥3 cm （χ²=10.24， P=0.001）， lymph node metastasis （χ²=5.63， P=0.018）， TNM stage Ⅲ （χ²=11.39， P=0.001）， and PIV ≥424.5 （χ²=34.59， P<0.001） in the bone metastasis group were higher than those in the non-metastasis group. Multivariate analysis showed that tumor longest diameter ≥3 cm （OR=3.02， 95%CI： 1.35-6.79， P=0.007）， lymph node metastasis （OR=2.38， 95%CI： 1.07-5.32， P=0.035）， TNM stage Ⅲ （OR=2.88， 95%CI： 1.31-6.32， P=0.009）， and PIV ≥424.5（OR=6.61， 95%CI： 2.99-14.59， P<0.001） were independent risk factors for bone metastasis in NSCLC patients. Conclusions PIV is elevated in NSCLC patients with tumor longest diameter ≥3 cm， lymph node metastasis， TNM stage Ⅲ， and bone metastasis. Elevated PIV has predictive value for bone metastasis， and may serve as a new biomarker for bone metastasis in NSCLC.

Key words: Carcinoma, non-small-cell lung, Prognosis, Bone metastasis

Wang Minjie, Lai Minghong, Cai Zhuoxin, Tang Yu, Zhang Caijin. Relationship between pan-immune inflammation value and clinicopathological features of non-small cell lung cancer and predictive analysis for bone metastasis[J]. Journal of International Oncology, 2026, 53(4): 207-212.

Figures/Tables 4

References 24

[1]	中华医学会肿瘤学分会. 中华医学会肺癌临床诊疗指南(2024版)[J]. 中华医学杂志, 2024, 104(34): 3175-3213. DOI: 10.3760/cma.j.cn112137-20240511-01092.
[2]	Wu XY, Matosevic S. Pathology, immunosuppression and NK cell immunotherapy of non-small cell lung cancer[J]. Crit Rev Oncol Hematol, 2025, 215: 104870. DOI: 10.1016/j.critrevonc.2025.104870.
[3]	Zhu YH, She JY, Sun R, et al. Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Front Immunol, 2024, 15: 1493773. DOI: 10.3389/fimmu.2024.1493773.
[4]	于德刚, 贾军梅. 肺癌骨转移治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(12): 789-793. DOI: 10.3760/cma.j.cn371439-20240608-00134.
[5]	Seo YJ, Kim KE, Jeong WK, et al. Effect of preoperative pan-immune-inflammation value on clinical and oncologic outcomes after colorectal cancer surgery: a retrospective study[J]. Ann Surg Treat Res, 2024, 106(3): 169-177. DOI: 10.4174/astr.2024.106.3.169. pmid: 38435496
[6]	Baba Y, Nakagawa S, Toihata T, et al. Pan-immune-inflammation value and prognosis in patients with esophageal cancer[J]. Ann Surg Open, 2021, 3(1): e113. DOI: 10.1097/AS9.0000000000000113.
[7]	Fu MD, Zhang XP, Shen F, et al. Prognostic value of peripheral blood neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, pan-immune-inflammation value and systemic immune-inflammation index for the efficacy of immunotherapy in patients with advanced gastric cancer[J]. Immunotherapy, 2024, 5: 113-119. DOI: 10.2217/imt-2024-0031.
[8]	中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2019版)[J]. 中华肿瘤杂志, 2020, 42(4): 257-287. DOI: 10.3760/cma.j.cn112152-20200120-00049.
[9]	Avancini A, Giaj-Levra N, Minuti G, et al. Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: a cross-sectional study[J]. Lung Cancer, 2025, 203: 108531. DOI: 10.1016/j.lungcan.2025.108531.
[10]	Lee J, Kim JA, An TJ, et al. Optimal timing for local ablative treatment of bone oligometastases in non-small cell lung cancer[J]. J Bone Oncol, 2023, 42: 100496. DOI: 10.1016/j.jbo.2023.100496.
[11]	Ishibashi Y, Kobayashi H, Ando T, et al. Prognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: a retrospective study[J]. World J Orthop, 2024, 15(12): 1155-1163. DOI: 10.5312/wjo.v15.i12.1155. pmid: 39744733
[12]	Asano Y, Hayashi K, Takeuchi A, et al. Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases[J]. Int Immunopharmacol, 2024, 136: 112276. DOI: 10.1016/j.intimp.2024.112276.
[13]	Xue M, Ma L, Zhang P, et al. New insights into non-small cell lung cancer bone metastasis: mechanisms and therapies[J]. Int J Biol Sci, 2024, 20(14): 5747-5763. DOI: 10.7150/ijbs.100960. pmid: 39494330
[14]	李添翼, 任粤, 宋震亚, 等. 泛免疫炎症指数在肿瘤预后疗效的研究进展[J]. 实用临床医药杂志, 2024, 28(5): 139-143. DOI: 10.7619/jcmp.20233348.
[15]	Zhou J, Wu DS, Zheng Q, et al. Development of a predictive model to predict postoperative bone metastasis in pathological Ⅰ-Ⅱ non-small cell lung cancer[J]. Transl Lung Cancer Res, 2024, 13(5): 998-1009. DOI: 10.21037/tlcr-23-866.
[16]	王海玉, 李波, 许小飞, 等. 非小细胞肺癌发生骨转移的危险因素分析[J]. 现代肿瘤医学, 2021, 29(13): 2274-2278. DOI: 10.3969/j.issn.1672-4992.2021.13.015.
[17]	Liu Y, Liu YK, Wang ST, et al. Utilizing machine learning algorithms for predicting risk factors for bone metastasis from right-sided colon carcinoma after complete mesocolic excision: a 10-year retrospective multicenter study[J]. Discov Oncol, 2024, 15(1): 463. DOI: 10.1007/s12672-024-01327-z. pmid: 39298052
[18]	Wang ZY, Wu X, Yang LY, et al. Prognostic value of pan-immune-inflammation in breast cancer patients with lymph node metastasis and neoadjuvant therapy[J]. Medicine (Baltimore), 2025, 104(47): e45713. DOI: 10.1097/MD.0000000000045713.
[19]	Russo P, Palermo G, Iacovelli R, et al. Comparison of PIV and other immune inflammation markers of oncological and survival outcomes in patients undergoing radical cystectomy[J]. Cancers (Basel), 2024, 16(3): 651. DOI: 10.3390/cancers16030651.
[20]	Liang W, Fu D. Analysis of the relationship between pan-immune-inflammation value and the clinical pathological characteristics and surgical prognosis of thyroid cancer[J]. Iran J Allergy Asthma Immunol, 2025, 24(5): 619-630. DOI: 10.18502/ijaai.v24i5.19745. pmid: 41143610
[21]	Wei YN, Mao DT, Liu TT, et al. The predictive value of PIV, PLR, LMR, NPR, and NLR for the prognosis of transarterial chemoembolization in patients with hepatocellular carcinoma combined with liver cirrhosis[J]. BMC Gastroenterol, 2025, 25(1): 315. DOI: 10.1186/s12876-025-03815-0.
[22]	Cao GJ, Liu QQ, Wen H, et al. The prognostic importance of the pan-immune-inflammation value (PIV) in lung cancer: a systematic review and meta-analysis[J]. Transl Lung Cancer Res, 2025, 14(10): 4357-4370. DOI: 10.21037/tlcr-2025-518.
[23]	Tong L, Wang S, Zhang RR, et al. High levels of SII and PIV are the risk factors of axillary lymph node metastases in breast cancer: a retrospective study[J]. Int J Gen Med, 2023, 16: 2211-2218. DOI: 10.2147/IJGM.S411592. pmid: 37287504
[24]	Bizzarri FP, Campetella M, Russo P, et al. Prognostic value of PLR, SIRI, PIV, SII, and NLR in non-muscle invasive bladder cancer: can inflammatory factors influence pathogenesis and outcomes?[J]. Cancers (Basel), 2025, 17(13): 2189. DOI: 10.3390/cancers17132189.

临床病理特征	例数	PIV	t/F值	P值	临床病理特征	例数	PIV	t/F值	P值
年龄（岁）					手术治疗
<60	83	358.12±64.44	-1.02	0.310	有	58	374.43±68.08	1.62	0.108
≥60	74	368.59±64.15	-1.02	0.310	无	99	357.34±61.45	1.62	0.108
性别					化疗
男	100	365.21±67.48	0.40	0.690	有	111	368.63±64.22	1.51	0.133
女	57	360.93±58.78	0.40	0.690	无	46	351.65±63.58	1.51	0.133
吸烟史					放疗
有	91	367.29±65.78	0.83	0.408	有	35	363.94±66.81	0.03	0.976
无	66	358.65±62.33	0.83	0.408	无	122	363.57±63.84	0.03	0.976
饮酒史					靶向治疗
有	47	363.57±63.93	-0.01	0.992	有	59	365.58±61.07	0.29	0.773
无	110	363.69±64.74	-0.01	0.992	无	98	362.50±66.44	0.29	0.773
肿瘤最长径（cm）					免疫治疗
<3	87	349.63±59.11	-3.09	0.002	有	46	363.67±67.94	0.01	0.998
≥3	70	381.09±66.59	-3.09	0.002	无	111	363.65±63.01	0.01	0.998
肿瘤部位					CEA（ng/ml）
左肺	90	346.73±65.63	0.24	0.809	<5	95	368.35±64.46	1.13	0.259
右肺	67	362.21±62.92	0.24	0.809	≥5	62	356.47±63.90	1.13	0.259
病理类型					CA19-9（U/ml）
腺癌	94	359.18±63.09	1.09	0.109	<37	101	366.00±66.71	0.61	0.541
鳞状细胞癌	49	369.79±65.91			≥37	56	359.43±60.04	0.61	0.541
其他	14	365.21±68.47			NSE（ng/ml）
分化程度					≤17	132	363.78±65.11	0.06	0.956
中低分化	95	362.43±67.73	-0.30	0.769	>17	25	363.00±61.06	0.06	0.956
高分化	62	365.53±59.13	-0.30	0.769	骨转移
淋巴结转移					是	57	428.04±49.65	13.39	<0.001
有	74	378.51±58.44	2.80	0.006	否	100	326.96±37.06	13.39	<0.001
无	83	350.37±66.67	2.80	0.006
TNM分期
Ⅰ~Ⅱ期	91	348.67±58.69	-3.56	0.001
Ⅲ期	66	384.32±66.36	-3.56	0.001

临床病理特征	骨转移组（n=57）	无骨转移组（n=100）	χ²值	P值	临床病理特征	骨转移组（n=57）	无骨转移组（n=100）	χ²值	P值
年龄（岁）					手术治疗
<60	25	58	2.91	0.088	有	25	33	1.84	0.175
≥60	32	42	2.91	0.088	无	32	67	1.84	0.175
性别					化疗
男	36	64	0.01	0.916	有	42	69	0.39	0.535
女	21	36	0.01	0.916	无	15	31	0.39	0.535
吸烟史					放疗
有	35	56	0.44	0.510	有	13	22	0.01	0.907
无	22	44	0.44	0.510	无	44	78	0.01	0.907
饮酒史					靶向治疗
有	18	29	0.12	0.734	有	24	35	0.78	0.377
无	39	71	0.12	0.734	无	33	65	0.78	0.377
肿瘤最长径（cm）					免疫治疗
<3	22	65	10.24	0.001	有	20	26	1.45	0.229
≥3	35	35	10.24	0.001	无	37	74	1.45	0.229
肿瘤部位					CEA（ng/ml）
左肺	32	58	0.05	0.821	<5	35	60	0.03	0.863
右肺	25	42	0.05	0.821	≥5	22	40	0.03	0.863
病理类型					CA19-9（U/ml）
腺癌	31	63	1.36	0.506	<37	38	63	0.21	0.645
鳞状细胞癌	21	28			≥37	19	37	0.21	0.645
其他	5	9			NSE（ng/ml）
分化程度					≤17	48	84	0.01	0.972
中低分化	34	61	0.03	0.868	>17	9	16	0.01	0.972
高分化	23	39	0.03	0.868	PIV
淋巴结转移					<424.5	21	83	34.59	<0.001
有	34	40	5.63	0.018	≥424.5	36	17	34.59	<0.001
无	23	60	5.63	0.018
TNM分期
Ⅰ~Ⅱ期	23	68	11.39	0.001
Ⅲ期	34	32	11.39	0.001

因素	β值	SE值	Wald χ²值	OR值	95%CI	P值
肿瘤最长径（≥3 cm/<3 cm）	1.11	0.41	7.17	3.02	1.35~6.79	0.007
淋巴结转移（有/无）	0.87	0.41	4.46	2.38	1.07~5.32	0.035
TNM分期（Ⅲ期/Ⅰ~Ⅱ期）	1.06	0.40	6.91	2.88	1.31~6.32	0.009
PIV（≥424.5/<424.5）	1.89	0.40	21.84	6.61	2.99~14.59	<0.001